Page last updated: 2024-08-25

albendazole sulfoxide and ER-Negative PR-Negative HER2-Negative Breast Cancer

albendazole sulfoxide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baglioni, MV; García, A; Lamas, MC; Leonardi, D; Menacho Márquez, M; Priotti, J; Rico, MJ	1

Other Studies

1 other study(ies) available for albendazole sulfoxide and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech, 2018, Volume: 19, Issue:8 Topics: Albendazole; Animals; Antiparasitic Agents; beta-Cyclodextrins; Biological Availability; Cell Proliferation; Cyclodextrins; Drug Repositioning; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Random Allocation; Treatment Outcome; Triple Negative Breast Neoplasms; X-Ray Diffraction	2018

Article

Year

Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.

AAPS PharmSciTech, 2018, Volume: 19, Issue:8

Topics: Albendazole; Animals; Antiparasitic Agents; beta-Cyclodextrins; Biological Availability; Cell Proliferation; Cyclodextrins; Drug Repositioning; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Random Allocation; Treatment Outcome; Triple Negative Breast Neoplasms; X-Ray Diffraction

2018